A Biochemist Spent Fifty Years Studying One Molecule. He Died In 2023. His Peptide Is Finally Reaching The Skin That Needs It Most.
Dr. Loren Pickart was not a famous scientist. He was a stubborn one. He published for more than five decades on a single three-amino-acid peptide, and when he died in Puyallup, Washington in October 2023, at 85, he was still working on it.
He also wasn't a dermatologist, a surgeon, or a plastic surgeon. He was a biochemist. He studied the molecule itself — how it was made, how it signalled, what it told cells to do — and he spent fifty years telling anyone who would listen that it mattered.
UCSF, 1973: A Doctoral Thesis Called "A Tripeptide From Human Serum"
Pickart arrived at UCSF in the late 1960s with an unusual research question for the era. His colleagues were chasing cancer. He wanted to study aging. His stated reason, which he repeated for the rest of his life, was that "that way I'd always have a job."
He noticed something in the lab: blood plasma from young donors behaved differently from blood plasma from older donors. When tissue from older donors was exposed to young plasma, the aging cells started producing proteins typical of young, healthy tissue. Something in young blood carried an instruction.
He isolated it in 1973. His doctoral thesis is titled, with characteristic literalism, "A Tripeptide From Human Serum." The molecule he found is three amino acids — glycine, histidine and lysine — bound to a single copper ion. One of the smallest signalling molecules ever isolated from human blood.
Chemists write it as GHK-Cu. On an ingredient label, it is Copper Tripeptide-1.
The Measurement That Explains Everything About Crepey Skin
Pickart spent the next five decades on this molecule. He published through the 1980s, 1990s and 2000s. He co-founded a biotech, took it public on the NASDAQ, left academia, came back, and kept publishing.
His single most important measurement was published in 2018, with Anna Margolina, in the International Journal of Molecular Sciences. He had asked a question nobody else had taken the time to answer: how much GHK-Cu does the human body actually carry at different ages?
That is the measurement that explains why the skin on arms, neck, chest and the backs of the hands goes crepey after fifty — and why the same skin on a thirty-year-old doesn't.
The fibroblasts aren't dying. They're idling. Pickart's peptide is the foreman that stopped showing up with the morning's work orders.
Why The Peptide Worked In A Serum But Never Reached The Body
Dermatologists started adding GHK-Cu to facial serums in the 1990s. It worked. It still works. Serum formulations were stable, the mechanism was documented, and the margin per ounce was high enough to make a facial category profitable.
But a facial serum, at $28–33 per ounce, is a face-only economic product. Covering the four body zones that lose the signal first — both arms, both hands, neck, chest — twice a day runs about $240 a month at facial-serum rates. No reasonable consumer stays on that protocol. So no body jar got made.
For fifty years the molecule Pickart isolated worked, in principle, on the body skin that needed it most. In practice, it never reached that skin at a sustainable price point. The science outran the formulation economics.
The First Body Formulation At A Payable Price
The product this article is about — a cream called Lumera, made by a small American skincare company — is the first mass-market attempt to deliver GHK-Cu in a body jar at a sustainable per-month cost.
Its formulators spent more than a year on two problems. First, delivering GHK-Cu at a stable concentration in a 100ml jar that could cover the four body zones for 30 days. Second, pairing it with the supply side of the equation that facial serums ignore: barrier lipids and humectants.
Post-menopausal body skin stops making enough of its own barrier lipids. Deliver a signal into skin that doesn't have the raw materials, and nothing happens. So Lumera pairs the GHK-Cu signal with shea butter (barrier), squalane (sebum mimic), sodium hyaluronate (water-draw), glycerin (water-hold), panthenol (calm) and vitamin E (protect).
They named the whole formulation the Cu-29 Signal + Supply Complex™, after copper's square on the periodic table — printed, deliberately, right on the jar.
What Pickart's Measurement Means For You
If you are a woman between 50 and 70, the measurement that matters to you is the 60% drop in GHK — and the 30% collagen loss documented in Obstetrics & Gynecology in the first five years after menopause. Those two declines converge, at the same time, on the same four body zones.
What the measurement means is simple: the skin you remember from your thirties is still built the same way. It is not getting the signal to keep rebuilding.
Pickart didn't invent Lumera. He wouldn't have cared who made the body jar, as long as somebody finally did. His peptide reaching the four zones that lost it first — at a price women can finish — is the end of a fifty-year arc.
What A Protocol Costs, Against What Pickart Saw Women Already Pay
In Memoriam, And Then: Try It
Pickart died on October 24, 2023. He left behind a published-research record more consistent and more focused than almost any skincare-adjacent researcher of his generation. The molecule he spent fifty years on is finally reaching the skin that first needed it.
There is one honest way to find out whether it matters for you: give it 90 days.
Start The 90-Day Signal Reset — 180-Day Guarantee
The protocol runs twice inside the guarantee window. Decide once you've seen your own skin.
Start the 90-Day Protocol Reader discount applied at checkout